Eterna Therapeutics Inc. (ERNAW) SEC Filings — 2024
17 SEC filings for Eterna Therapeutics Inc. (ERNAW) in 2024.
Filings
- Eterna Therapeutics Files Q3 2024 10-Q — 10-Q · Nov 12, 2024
- Eterna Therapeutics Files S-1 with SEC — S-1 · Nov 5, 2024
- Eterna Therapeutics Files 8-K with Key Corporate Updates — 8-K · Oct 29, 2024
- Eterna Therapeutics Files Definitive Proxy Statement — DEF 14A · Oct 7, 2024
- Eterna Therapeutics Terminates Material Definitive Agreement — 8-K · Sep 27, 2024
- Eterna Therapeutics Reports Material Agreement and Financial Obligations — 8-K · Sep 25, 2024
- Eterna Therapeutics Faces Nasdaq Delisting — 8-K · Sep 23, 2024
- Eterna Therapeutics Sells Subsidiary — 8-K · Aug 19, 2024
- Eterna Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 13, 2024
- Eterna Therapeutics Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 14, 2024
- Eterna Therapeutics Faces Nasdaq Delisting Warning — 8-K · Mar 22, 2024
- Eterna Therapeutics Inc. Files Amendment to Annual Report — 10-K/A · Mar 18, 2024
- Eterna Therapeutics Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 14, 2024
- Eterna Therapeutics Announces Leadership Changes & Compensation Arrangements — 8-K · Feb 16, 2024
- John D. Halpern Divests Entire Stake in Eterna Therapeutics — SC 13G/A · Jan 31, 2024
- Nicholas Jason Singer Amends Eterna Therapeutics Stake — SC 13G/A · Jan 19, 2024
- Eterna Therapeutics (ERNA) Delisted from Nasdaq — 8-K · Jan 19, 2024